66 Results
Sort By:
Published on October 12, 2023
China-headquartered MediLink Therapeutics has entered into a deal with BioNTech for development of a next-generation antibody-drug conjugate candidate (ADC) against Human Epidermal Growth Factor Receptor 3 (HER3). With an upfront payment of $70M and plenty of additional development, regulatory, and commercial milestone payments, the deal could be worth over $1 billion.…
Published on April 4, 2023
The field of ADCs is heating up, as the FDA just granted PADCEV (Seagen’s enfortumab vedotin-ejfv) and KEYTRUDA (Merck’s pembrolizumab) accelerated approval as a combination therapy for the treatment of certain adult patients with advanced urothelial cancer. Final approval is contingent upon results from a follow up trial (EV-302). Antibody drug conjugates (ADCs) are…
Published on January 30, 2024
One of the most competitive fields in pharma today involves antibody drug conjugates (ADCs), a market estimated to be worth almost $20B already. This week the FDA accepted the supplemental Biologics License Application (sBLA) for ADC Enhertu (fam-trastuzumab deruxtecan-nxki) and granted it Priority Review. Enhertu is a HER2-directed ADC being…
Published on January 5, 2024
Roche has inked a collaboration potentially worth more than $2B with precision oncology company MOMA Therapeutics. The deal provides the big pharma with access to MOMA’s proprietary KnowledgeBase platform, which was built to identify novel drug targets involved in promoting cancer cell growth and survival. This follows a $50 million…
Published on December 19, 2023
Two new deals around antibody drug conjugates (ADCs) were just struck. Pfizer will develop and commercialize Nona Biosciences’ MSLN-targeted ADC HBM9033 in a deal worth potentially $1B+. Meanwhile, Biocytogen Pharmaceuticals announced an antibody evaluation, option, and license agreement with Ona Therapeutics. The deal includes an option to exclusively license selected…
Published on December 12, 2023
Bristol Myers Squibb (BMS) will co-develop SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC) in the United States. The deal is worth potentially more than $8B. “Recent BL-B01D1 trials have shown broad potential across different solid tumors as well as a manageable safety profile,” said Yi Zhu, CEO…
Published on December 1, 2023
AbbVie continues the ADC party and beefs up its anti-solid tumor portfolio with the acquisition of ImmunoGen for $10.1B. ImmuoGen’s flagship cancer therapy is Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), according to an announcement yesterday. This has been the year of the…
Published on October 20, 2023
In a $4B upfront deal, Merck is acquiring three of Daiichi Sankyo’s antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The two companies will jointly develop and commercialize these drugs worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Total potential consideration…
Published on September 7, 2023
Scientists at Montefiore Einstein Cancer Center (MECC) have developed a new test for detecting a type of cervical cancer that is often missed by traditional Pap tests. This breakthrough could have significant implications for cervical cancer screening. The findings of their research are published in the Journal of the National…
Published on May 18, 2023
Sony Corporation and Astellas Pharma have signed an agreement to discover a novel antibody-drug conjugate (ADC) platform in oncology based on Sony’s unique polymeric material—the KIRAVIA Backbone, which is made using the same organic polymer technology incorporated in the company’s proprietary KIRAVIA dyesTM. Terms of the deal were not released.…
Published on May 9, 2023
In the latest high profile antibody drug conjugate (ADC) deal, this week Hangzhou-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration agreement with Eisai for its lead ADC BB-1701, which is in Phase I/II in China and the U.S. BB-1701 has an eribulin-payload directed against Human Epidermal Growth Factor Receptor…
Published on April 20, 2023
Bristol Myers Squibb joined the antibody-drug conjugate (ADC) rush as it announced an agreement with Tubulis to develop differentiated ADCs using the company’s proprietary P5 conjugation platform. The deal covers the development of a selected number of highly differentiated ADCs to treat solid tumors. There are already more than a…
Published on April 18, 2023
As part of the annual meeting of the American Association for Cancer Research (AACR) in Orlando, FL, researchers from the Perelman School of Medicine at the University of Pennsylvania have not only identified a new target for drug-resistant ovarian cancer but also provided supporting evidence for a potential treatment approach.…
Published on April 3, 2023
BioNTech is adding ADCs to its portfolio through a deal with China-based Duality Biologics (DualityBio). The two companies will collaborate on development, manufacturing, and commercialization of two antibody drug conjugate (ADC) assets for cancer and autoimmune disease, including Duality’s lead candidate (DB-1303), which is currently in Phase II. DualityBio will…
Published on March 14, 2023
Pfizer is beefing up its oncology portfolio by acquiring Seagen for $229 per share, for a total deal value of $43 billion. Pfizer’s move came after Merck’s failed attempt to acquire the biotech. That deal is believed to have fallen flat after a price could not be negotiated, GEN recently…